TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

por Richard Hill, Patricia A. Madureira, Bibiana Ferreira, Inês Baptista, Susana Machado, Laura Colaço, Marta dos Santos, Ningshu Liu, Ana Dopazo, Selma Ugurel, Angyal Adrienn, Endre Kiss-Toth, Murat Isbilen, Ali O. Gure, Wolfgang Link
Publicado 2017